Michelle Renee Lewis, the Chief Accounting Officer at PACS Group, Inc. (NASDAQ:PACS), has executed a series of stock sales totaling 15,000 shares. The transactions, valued at approximately $675,424, were carried out in early July 2026 under a Rule 10b5-1 trading plan established in March of that year. This executive activity occurs against a backdrop of robust corporate performance for PACS Group, which recently reported first-quarter earnings that exceeded market forecasts and announced a significant acquisition in the skilled nursing sector.
The sales were executed on July 1, July 2, and July 6, 2026. The weighted average price per share for these transactions ranged from $45.0141 to $45.0406. Following the execution of these sales, Ms. Lewis retains a direct holding of 355,338 shares in PACS Group common stock.
The timing of these transactions is notable given the recent performance of PACS Group's equity. The stock is currently trading near its 52-week high of $45.89. Over the past year, the shares have experienced a substantial appreciation of 242%. Despite this strong performance, analysis from InvestingPro suggests that the stock may be overvalued relative to its Fair Value. Detailed research and a list of overvalued stocks are available for further investor consideration.
In terms of corporate fundamentals, PACS Group reported strong financial results for the first quarter of 2026. The company surpassed earnings expectations, reporting an earnings per share (EPS) of $0.50, which exceeded the forecasted $0.44. Revenue for the quarter reached $1.42 billion, marking an 11% increase compared to the previous year.
Beyond financial reporting, PACS Group announced a definitive agreement to acquire 34 skilled nursing facilities from Eduro Healthcare. These facilities are distributed across six western states and will add 3,633 skilled nursing beds to the company's portfolio. In response to these developments, Truist Securities reiterated a Buy rating on PACS Group. The firm highlighted the company's strong positioning, attractive demand trends, clinical and operational execution, and focus on regulatory investment activity.
Market activity in PACS Group options also saw a significant increase, with 7,248 contracts traded, primarily consisting of call options. These recent developments underscore PACS Group's strategic moves and financial performance in the market.